Prospective randomized clinical trial assessing the efficacy of denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs

Katherine A Skorupski, G. M. Hammond, A. M. Irish, Michael S Kent, T. A. Guerrero, C. O. Rodriguez, D. W. Griffin

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Increases in liver enzymes occur in up to 86% of dogs receiving CCNU and can result in treatment delay or early discontinuation of treatment. Denamarin contains S-adenosylmethionine and silybin, both of which have been investigated as treatments for various liver diseases. Hypothesis: Dogs on CCNU receiving Denamarin have lower alanine aminotransferase (ALT) activity than dogs not receiving Denamarin. Dogs on Denamarin are less likely to require treatment delay because of hepatopathy and are more likely to complete their prescribed course of CCNU. Animals: Dogs with lymphoma, mast cell tumor, or histiocytic sarcoma that were prescribed CCNU with or without corticosteroids and with normal ALT activity were eligible for enrollment. Methods: Dogs were prospectively randomized to receive either concurrent Denamarin during CCNU chemotherapy or to receive CCNU alone. Liver-specific laboratory tests were run before each dose of CCNU. Results: Increased liver enzyme activity occurred in 84% of dogs receiving CCNU alone and in 68% of dogs on concurrent Denamarin. Dogs receiving CCNU alone had significantly greater increases in ALT, aspartate aminotransferase, alkaline phosphatase, and bilirubin and a significantly greater decrease in serum cholesterol concentrations than dogs receiving concurrent Denamarin. Dogs receiving CCNU alone were significantly more likely to have treatment delayed or discontinued because of increased ALT activity. Conclusions: Increased liver enzyme activity occurs commonly in dogs receiving CCNU chemotherapy. These results support the use of concurrent Denamarin to minimize increased liver enzyme activity in dogs receiving CCNU chemotherapy. Denamarin treatment also increases the likelihood of dogs completing a prescribed CCNU course.

Original languageEnglish (US)
Pages (from-to)838-845
Number of pages8
JournalJournal of Veterinary Internal Medicine
Volume25
Issue number4
DOIs
StatePublished - Jul 2011

Fingerprint

Lomustine
randomized clinical trials
Randomized Controlled Trials
Dogs
neoplasms
dogs
Neoplasms
Alanine Transaminase
alanine transaminase
liver
Liver
drug therapy
enzyme activity
Enzymes
Drug Therapy
Mast-Cell Sarcoma
Therapeutics
Histiocytic Sarcoma
S-Adenosylmethionine
S-adenosylmethionine

Keywords

  • Lomustine
  • S-adenosylmethionine
  • Silybin

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Prospective randomized clinical trial assessing the efficacy of denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs. / Skorupski, Katherine A; Hammond, G. M.; Irish, A. M.; Kent, Michael S; Guerrero, T. A.; Rodriguez, C. O.; Griffin, D. W.

In: Journal of Veterinary Internal Medicine, Vol. 25, No. 4, 07.2011, p. 838-845.

Research output: Contribution to journalArticle

@article{aca4ddcbe2b441f181278518fa757658,
title = "Prospective randomized clinical trial assessing the efficacy of denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs",
abstract = "Background: Increases in liver enzymes occur in up to 86{\%} of dogs receiving CCNU and can result in treatment delay or early discontinuation of treatment. Denamarin contains S-adenosylmethionine and silybin, both of which have been investigated as treatments for various liver diseases. Hypothesis: Dogs on CCNU receiving Denamarin have lower alanine aminotransferase (ALT) activity than dogs not receiving Denamarin. Dogs on Denamarin are less likely to require treatment delay because of hepatopathy and are more likely to complete their prescribed course of CCNU. Animals: Dogs with lymphoma, mast cell tumor, or histiocytic sarcoma that were prescribed CCNU with or without corticosteroids and with normal ALT activity were eligible for enrollment. Methods: Dogs were prospectively randomized to receive either concurrent Denamarin during CCNU chemotherapy or to receive CCNU alone. Liver-specific laboratory tests were run before each dose of CCNU. Results: Increased liver enzyme activity occurred in 84{\%} of dogs receiving CCNU alone and in 68{\%} of dogs on concurrent Denamarin. Dogs receiving CCNU alone had significantly greater increases in ALT, aspartate aminotransferase, alkaline phosphatase, and bilirubin and a significantly greater decrease in serum cholesterol concentrations than dogs receiving concurrent Denamarin. Dogs receiving CCNU alone were significantly more likely to have treatment delayed or discontinued because of increased ALT activity. Conclusions: Increased liver enzyme activity occurs commonly in dogs receiving CCNU chemotherapy. These results support the use of concurrent Denamarin to minimize increased liver enzyme activity in dogs receiving CCNU chemotherapy. Denamarin treatment also increases the likelihood of dogs completing a prescribed CCNU course.",
keywords = "Lomustine, S-adenosylmethionine, Silybin",
author = "Skorupski, {Katherine A} and Hammond, {G. M.} and Irish, {A. M.} and Kent, {Michael S} and Guerrero, {T. A.} and Rodriguez, {C. O.} and Griffin, {D. W.}",
year = "2011",
month = "7",
doi = "10.1111/j.1939-1676.2011.0743.x",
language = "English (US)",
volume = "25",
pages = "838--845",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Prospective randomized clinical trial assessing the efficacy of denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs

AU - Skorupski, Katherine A

AU - Hammond, G. M.

AU - Irish, A. M.

AU - Kent, Michael S

AU - Guerrero, T. A.

AU - Rodriguez, C. O.

AU - Griffin, D. W.

PY - 2011/7

Y1 - 2011/7

N2 - Background: Increases in liver enzymes occur in up to 86% of dogs receiving CCNU and can result in treatment delay or early discontinuation of treatment. Denamarin contains S-adenosylmethionine and silybin, both of which have been investigated as treatments for various liver diseases. Hypothesis: Dogs on CCNU receiving Denamarin have lower alanine aminotransferase (ALT) activity than dogs not receiving Denamarin. Dogs on Denamarin are less likely to require treatment delay because of hepatopathy and are more likely to complete their prescribed course of CCNU. Animals: Dogs with lymphoma, mast cell tumor, or histiocytic sarcoma that were prescribed CCNU with or without corticosteroids and with normal ALT activity were eligible for enrollment. Methods: Dogs were prospectively randomized to receive either concurrent Denamarin during CCNU chemotherapy or to receive CCNU alone. Liver-specific laboratory tests were run before each dose of CCNU. Results: Increased liver enzyme activity occurred in 84% of dogs receiving CCNU alone and in 68% of dogs on concurrent Denamarin. Dogs receiving CCNU alone had significantly greater increases in ALT, aspartate aminotransferase, alkaline phosphatase, and bilirubin and a significantly greater decrease in serum cholesterol concentrations than dogs receiving concurrent Denamarin. Dogs receiving CCNU alone were significantly more likely to have treatment delayed or discontinued because of increased ALT activity. Conclusions: Increased liver enzyme activity occurs commonly in dogs receiving CCNU chemotherapy. These results support the use of concurrent Denamarin to minimize increased liver enzyme activity in dogs receiving CCNU chemotherapy. Denamarin treatment also increases the likelihood of dogs completing a prescribed CCNU course.

AB - Background: Increases in liver enzymes occur in up to 86% of dogs receiving CCNU and can result in treatment delay or early discontinuation of treatment. Denamarin contains S-adenosylmethionine and silybin, both of which have been investigated as treatments for various liver diseases. Hypothesis: Dogs on CCNU receiving Denamarin have lower alanine aminotransferase (ALT) activity than dogs not receiving Denamarin. Dogs on Denamarin are less likely to require treatment delay because of hepatopathy and are more likely to complete their prescribed course of CCNU. Animals: Dogs with lymphoma, mast cell tumor, or histiocytic sarcoma that were prescribed CCNU with or without corticosteroids and with normal ALT activity were eligible for enrollment. Methods: Dogs were prospectively randomized to receive either concurrent Denamarin during CCNU chemotherapy or to receive CCNU alone. Liver-specific laboratory tests were run before each dose of CCNU. Results: Increased liver enzyme activity occurred in 84% of dogs receiving CCNU alone and in 68% of dogs on concurrent Denamarin. Dogs receiving CCNU alone had significantly greater increases in ALT, aspartate aminotransferase, alkaline phosphatase, and bilirubin and a significantly greater decrease in serum cholesterol concentrations than dogs receiving concurrent Denamarin. Dogs receiving CCNU alone were significantly more likely to have treatment delayed or discontinued because of increased ALT activity. Conclusions: Increased liver enzyme activity occurs commonly in dogs receiving CCNU chemotherapy. These results support the use of concurrent Denamarin to minimize increased liver enzyme activity in dogs receiving CCNU chemotherapy. Denamarin treatment also increases the likelihood of dogs completing a prescribed CCNU course.

KW - Lomustine

KW - S-adenosylmethionine

KW - Silybin

UR - http://www.scopus.com/inward/record.url?scp=79960556328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960556328&partnerID=8YFLogxK

U2 - 10.1111/j.1939-1676.2011.0743.x

DO - 10.1111/j.1939-1676.2011.0743.x

M3 - Article

VL - 25

SP - 838

EP - 845

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 4

ER -